(1987) Treatment of advanced prostatic cancer. Urol Clin North Am, 14, 353-71.Sogani,P.C. and Fair,W.R. (1987) Treatment of advanced prostatic cancer. Urol. Clin. North Am., 14, 353-371.Sogani PC & Fair WR 1987 Treatment of advanced prostatic cancer. Urologic Clinics of North ...
Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol. 2007;9(suppl 1):S3-S8. Bianco FJ, Dotan ZA, Kattan MW, Fearn PA, Scher HI, Eastham JA, Scardino PT. Duration of response to androgen deprivation therapy and survival after subsequent biochemical relapse in ...
Galeterone for the treatment of advanced prostate cancer: the evidence to datedoi:10.2147/DDDT.S93941ARsplicevariantsAR-V7castration-resistant... Diogo,A,Bastos,... - 《Drug Design Development & Therapy》 被引量: 9发表: 2016年 Abiraterone and other novel androgen-directed strategies for the tre...
Ketoconazole and liarozole in the treatment of advanced prostatic cancer Background. Ketoconazole, an imidazole derivative, is an orally active antifungal agent. In high doses (400 mg three times a day), it inhibits the biosynth... C,Mahler,J,... - 《Cancer》 被引量: 231发表: 1993年 ...
Localized prostate cancer may be cured with surgery and/or radiotherapy, while advanced stage disease can be managed with an array of therapeutics including androgen receptor pathway inhibition (ARPI) therapy, taxane-based therapies, immunotherapy, poly(ADP-ribose) polymerase (PARP) inhibitors, and ...
Male hormones, specifically testosterone, fuel the growth of prostate cancer. By reducing the amount and activity of testosterone, the growth of advanced prostate cancer is slowed. Hormone (endocrine) therapy, known as androgen ablation or androgen suppression therapy, is the main treatment for advanc...
In the treatment of advanced prostate cancer Drop TestosteroneFast Patients on FIRMAGON®reached their treatmentgoal in 3 days1 The goal of hormone therapy is to lower Testosterone (T) levels. WithFIRMAGON, you don't have to wait. PSA reduction usually followsTdrop.2 ...
Discusses the treatment of advanced prostate cancer. The case of a 70-year-old man; Details about androgens and the prostate gland; Androgen withdrawal therapy; Responses to androgen withdrawal therapy; Controversial issues in advanced prostate cancer; Quality-of-life issues; Hormone-refractory prostate...
An increased understanding of basic immunology, combined with the identification of various tumour-associated antigens, has fuelled the development of novel immunotherapy approaches for various cancers, including prostate cancer. In this Review, Karan an
Prostate cancer is the second most common cancer in men, accounting for 14.1% of new cancer cases in 2020. The aggressiveness of prostate cancer is highly variable, depending on its grade and stage at the time of diagnosis. Despite recent advances in prostate cancer treatment, some patients sti...